HIV facial lipoatrophy: causes and treatment options.
BACKGROUND
Human immunodeficiency virus (HIV)-associated facial lipoatrophy is becoming epidemic and may seriously affect quality of life.


OBJECTIVE
To review the possible causes and treatment options for HIV facial lipoatrophy.


METHODS
This article is based on a review of the medical literature and the author's clinical experience in treating HIV facial


CONCLUSIONS
Although absorbable injectable fillers and implants are helpful in treating HIV facial lipoatrophy, they are limited by cost and the short duration of correction. Newer forms of longer-lasting fillers (poly-L-lactic acid [Sculptra]) and permanent injectable fillers (liquid injectable silicone) are proving useful for treatment of this condition.
Jones
Derek
D
Division of Dermatology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA.
D000273:Adipose Tissue / Q000637:transplantation; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D001672:Biocompatible Materials / Q000008:administration & dosage*; D003094:Collagen / Q000008:administration & dosage; D005145:Face; D005206:Fascia Lata / Q000637:transplantation; D039682:HIV-Associated Lipodystrophy Syndrome / Q000628:therapy*; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D019344:Lactic Acid / Q000008:administration & dosage; D011091:Polyesters; D011108:Polymers / Q000008:administration & dosage*; D019904:Polymethyl Methacrylate; D011138:Polytetrafluoroethylene; D019736:Prostheses and Implants; D012828:Silicones / Q000008:administration & dosage
C440568:Alloderm; D001672:Biocompatible Materials; D011091:Polyesters; D011108:Polymers; D012828:Silicones; D019344:Lactic Acid; C033616:poly(lactide); D011138:Polytetrafluoroethylene; D006820:Hyaluronic Acid; D003094:Collagen; D019904:Polymethyl Methacrylate; C445361:Restylane